



Oregon Prescription Drug Affordability Board (PDAB) Regular Meeting
Wednesday, June 18, 2025
Minutes approved by the board on July 17, 2025

Web link to the meeting video: <https://youtu.be/RP3A5s6hiwc>

Web link to the meeting materials: <https://dfr.oregon.gov/pdab/Documents/20250618-PDAB-document-package.pdf>

Call to order: Chair Shelley Bailey called the meeting to order at 9:03 a.m. and roll was called.

Board members present: Chair Shelley Bailey, Dan Hartung, Lauri Hoagland, Robert Judge, Chris Laman, John Murray (arrived at 9:26 am due to a local power outage)

Absent: Vice Chair Amy Burns, Dan Kennedy

The board provided American Sign Language during the meeting.

Declaration of conflict of interest, meetings with entities or individuals related to board activities, or testifying before the Legislature: John Murray provided a statement later in the meeting. View at video minute [01:24:03](#).

Approval of board minutes: Chair Bailey asked for a motion and second to approve the board minutes as shown on [Pages 3-5](#) of the agenda materials. The minutes were revised to include all the speakers from the May 21, 2025 meeting. Chris Laman made a motion to approve the minutes and Lauri Hoagland provided a second. The motion failed. The board voted again near the end of the meeting when more board members were present and the motion passed. View the first vote at video minute [00:04:15](#) and the second vote at video minute [03:01:48](#).

First MOTION to approve the May 21, 2025, minutes

Board Vote:

Yes: Dan Hartung, Lauri Hoagland, Chris Laman, Chair Shelley Bailey

No: None

Abstain: Robert Judge

Absent: Vice Chair Amy Burns, Dan Kennedy, John Murray

Motion failed 4-0

Second MOTION to approve the May 21, 2025, minutes

Board Vote:

Yes: Dan Hartung, Lauri Hoagland, Chris Laman, John Murray, Chair Shelley Bailey

No: None

Abstain: Robert Judge

Absent: Vice Chair Amy Burns, Dan Kennedy,

Motion passed 5-0



Executive director's program update: Ralph Magrish, executive director, Oregon Prescription Drug Affordability Board & Drug Price Transparency Program, provided a program update. View the video at minute [00:04:39](#).

Legislative update: Jesse O'Brien, Division of Financial Regulation (DFR) policy manager, provided an update on prescription drug-related bills proposed in the Oregon Legislative session as shown on [Pages 6-7](#) of the agenda materials. View the video at minute [00:4:47](#).

General Public comment: Chair Bailey called on the people who signed up in advance to speak to the board: Gaby Gardiner, Basic Rights Oregon; Lorren Sandt, Caring Ambassadors Program, Inc.; Tiffany Westrich-Robertson, EACH Coalition; Mary Anne Cooper, Regence BlueCross BlueShield of Oregon; Katie Chandra, Genentech; Jessica McBride, Oregon Coalition for Affordable Prescriptions; and Dharia McGrew, PhRMA. The board received 14 written comments, which are posted on the [PDAB website](#). View the speakers at video minute [00:16:42](#).

Board review and vote for updated data subset list of prescription drugs and insulin products pursuant to OAR 925-200-0010: The board reviewed the patient survey results, the list of orphan drugs, the subset list of 27 prescription drugs from the March 19 meeting, and the subset list of insulin glargine from the April 16 meeting as shown on [Pages 8-23](#) in the agenda materials. The board also reviewed the data dashboard, which is posted on the [PDAB website](#). The board voted on an updated list of 23 medications for review in 2025. See the list below. It is also posted on the [PDAB website](#). View the discussion at video minute [00:43:30](#).

MOTION to approve the data subset list of prescription drugs as discussed by the board today.

Motion made by Chris Laman with a second by Lauri Hoagland.

Board vote:

Yes: Dan Hartung, Lauri Hoagland, Robert Judge, Chris Laman, John Murray, Chair Shelley Bailey

No: None

Absent for the vote: Vice Chair Amy Burns, Dan Kennedy

Motion passed 6-0

MOTION to approve the data subset list of insulin as discussed by the board today.

Motion made by John Murray with a second by Lauri Hoagland.

Board vote:

Yes: Dan Hartung, Lauri Hoagland, Robert Judge, Chris Laman, John Murray, Chair Shelley Bailey

No: None

Absent for the vote: Vice Chair Amy Burns, Dan Kennedy

Motion passed 6-0

Announcements: Chair Bailey announced the next meeting will be July 16, 2025, at 9 a.m.

Adjournment: Chair Bailey adjourned the meeting at 12:15 p.m. with all board members in agreement. View at minute [03:03:54](#).



Prescription medication list for the Oregon PDAB review in 2025

Review grouping number	Therapy class	Drug name	Non-proprietary name
1	Antipsychotics & Antimanic agents	Vraylar	Cariprazine HCl
1	Cardiovascular agents – misc.	Entresto	Sacubitril; Valsartan
1	Migraine product	Ajovy	Fremanezumab-vfrm
1	Migraine product	Emgality	Galcanezumab-gnlm
1	Migraine product	Nurtec	Rimegepant/rimegepant sulfate
1	Migraine product	Ubrelvy	Ubrogepant
2	Antiasthmatic and bronchodilator	Trelegy	Fluticasone furoate; Umeclidinum bromide; Vilanterol trifenate
2	Anticoagulants	Eliquis	Apixaban
2	Anticoagulants	Xarelto	Rivaroxaban
2	Dermatological	Cosentyx	Secukinumab
2	Digestive Aids	Creon	Pancrelipase (Amylase; Lipase; Protease)
3	Antidiabetics	Jardiance	Empagliflozin
3	Antidiabetics	Mounjaro	Tirzepatide
3	Antidiabetics	Ozempic	Semaglutide
3	Antidiabetics	Rybelsus	Semaglutide
3	Antidiabetics	Trulicity	Dulaglutide
4	Insulin product	Basaglar KwikPen	Insulin Glargine
4	Insulin product	Insulin Glardine-yfgn	Insulin Glargine
4	Insulin product	Lantus	Insulin Glargine
4	Insulin product	Lantus SolorStar	Insulin Glargine
4	Insulin product	Semglee (yfgn)	Insulin Glargine
4	Insulin product	Toujeo Max SolorStar	Insulin Glargine
4	Insulin product	Toujeo SoloStar	Insulin Glargine